| 1 | choice | 8,936 |
| 2 | sight | 104 |
| 3 | tale | 15 |
| 4 | codependency | 13 |
| 5 | conscience | 10 |
| 6 | co-consumption | 9 |
| 7 | fallibility | 8 |
| 8 | force-displacement | 8 |
| 9 | fancy | 7 |
| 10 | pocts | 7 |
| 11 | yews | 7 |
| 12 | domicile | 6 |
| 13 | swahili | 6 |
| 14 | 'value | 5 |
| 15 | pseudo-foveas | 5 |
| 16 | xxmd | 5 |
| 17 | 500ms | 4 |
| 18 | druglikeness | 4 |
| 19 | gonopod | 4 |
| 20 | humanization | 4 |
| 21 | legitimisation | 4 |
| 22 | milk/kg | 4 |
| 23 | sclerotization | 4 |
| 24 | biofunctionality | 3 |
| 25 | coffee/day | 3 |
| 26 | cross-immunity | 3 |
| 27 | dysautonomias | 3 |
| 28 | lepchas | 3 |
| 29 | lynchpin | 3 |
| 30 | mega-doses | 3 |
| 31 | mystique | 3 |
| 32 | overseers | 3 |
| 33 | professorship | 3 |
| 34 | protonation/deprotonation | 3 |
| 35 | re-screening | 3 |
| 36 | ring-closure | 3 |
| 37 | secnidazol | 3 |
| 38 | set-shift | 3 |
| 39 | single-doses | 3 |
| 40 | sorafenib+nutlin-3 | 3 |
| 41 | surname | 3 |
| 42 | trans-isomers | 3 |
| 43 | 0.82-6.0 | 2 |
| 44 | 20μg/ml | 2 |
| 45 | 4.4°c | 2 |
| 46 | 45ºc | 2 |
| 47 | aem-70 | 2 |
| 48 | chaihu-shaoyao | 2 |
| 49 | galloylation | 2 |
| 50 | indianization | 2 |
| 51 | keflex | 2 |
| 52 | nac-cc | 2 |
| 53 | nits | 2 |
| 54 | non-inferioritylequivalence | 2 |
| 55 | oil/day/person | 2 |
| 56 | ovacheck | 2 |
| 57 | photomicrography | 2 |
| 58 | positivization | 2 |
| 59 | postcrania | 2 |
| 60 | radiofluorination | 2 |
| 61 | radioopacity | 2 |
| 62 | reachability | 2 |
| 63 | resistome | 2 |
| 64 | scientology | 2 |
| 65 | self-pyrolysis | 2 |
| 66 | sero-efficacy | 2 |
| 67 | somato-types | 2 |
| 68 | stereoinduction | 2 |
| 69 | storvas | 2 |
| 70 | £45 | 2 |
| 71 | 'antibacterials | 1 |
| 72 | 'assessments | 1 |
| 73 | 'preparation | 1 |
| 74 | 0.005-5μg/ml | 1 |
| 75 | 0.01-10ng/ml | 1 |
| 76 | 0.026-0.341 | 1 |
| 77 | 0.030±0.004μg/kg/min | 1 |
| 78 | 0.06-1.6μg/ml | 1 |
| 79 | 0.070±0.017μg/kg/min | 1 |
| 80 | 0.1-10μg/ml | 1 |
| 81 | 0.20-401.12μg/ml | 1 |
| 82 | 0.5-200ng/ml | 1 |
| 83 | 0.66±0.47mm | 1 |
| 84 | 0.805-0.907 | 1 |
| 85 | 0.84∼0.93 | 1 |
| 86 | 0.9869 | 1 |
| 87 | 1.57-1.62 | 1 |
| 88 | 1.59kwh/kgcu | 1 |
| 89 | 1.73-2.77 | 1 |
| 90 | 1/2/3/4/37/20/4/3 | 1 |
| 91 | 100g/d | 1 |
| 92 | 100µg/day | 1 |
| 93 | 13.6-14.1μm | 1 |
| 94 | 130,013 | 1 |
| 95 | 1350-1400°c | 1 |
| 96 | 137-138°c | 1 |
| 97 | 15-18°c | 1 |
| 98 | 177°c | 1 |
| 99 | 180,000°c/min | 1 |
| 100 | 1:5463 | 1 |
| 101 | 1hz-rtms | 1 |
| 102 | 1hz/20hz | 1 |
| 103 | 2-4msv | 1 |
| 104 | 2-furoyl-ligrlo-amide | 1 |
| 105 | 2.1g | 1 |
| 106 | 2.5bar | 1 |
| 107 | 2.9w/kg | 1 |
| 108 | 23.64-1182ng/ml | 1 |
| 109 | 27.0mpa | 1 |
| 110 | 28*/28* | 1 |
| 111 | 28.1°c | 1 |
| 112 | 3.3-8.9 | 1 |
| 113 | 3.6±1.9μg/kg/min | 1 |
| 114 | 4-20°c | 1 |
| 115 | 4.1/patient-year | 1 |
| 116 | 4u/kg | 1 |
| 117 | 5-3000ng/ml | 1 |
| 118 | 5.00-400ng/ml | 1 |
| 119 | 500w | 1 |
| 120 | 57,500 | 1 |
| 121 | 6.4-247.5 | 1 |
| 122 | 708.3 | 1 |
| 123 | 771.8 | 1 |
| 124 | 9.880 | 1 |
| 125 | a-pcs | 1 |
| 126 | accuracy/latency | 1 |
| 127 | amniofusion | 1 |
| 128 | anthracycline-therapy | 1 |
| 129 | antipsychotic-augmentation | 1 |
| 130 | at/aml | 1 |
| 131 | atomoxetine/placebo | 1 |
| 132 | beta-sympatomimetics | 1 |
| 133 | biometabolites | 1 |
| 134 | biovolumes | 1 |
| 135 | c50sevo | 1 |
| 136 | ceftriaxone+vancomycin | 1 |
| 137 | cephapirin/ml | 1 |
| 138 | cetuximab+chemoradiation | 1 |
| 139 | citalopran | 1 |
| 140 | co-acupressure | 1 |
| 141 | collimomycins | 1 |
| 142 | ct-ridc | 1 |
| 143 | cyclopheron | 1 |
| 144 | d=1.203 | 1 |
| 145 | double-slit | 1 |
| 146 | drinking-with-partner | 1 |
| 147 | education/preparation | 1 |
| 148 | efficacy/evidence | 1 |
| 149 | endosheaths | 1 |
| 150 | ethnopharmacovigilance | 1 |
| 151 | euro315 | 1 |
| 152 | euro99 | 1 |
| 153 | family-screening | 1 |
| 154 | femn4ox/mcm-41 | 1 |
| 155 | feneticillin | 1 |
| 156 | flow-sorting | 1 |
| 157 | freshness-indices | 1 |
| 158 | g=3 | 1 |
| 159 | gaba-agonism | 1 |
| 160 | gabapentin-pregabalin | 1 |
| 161 | galactolipid/day | 1 |
| 162 | gum/day | 1 |
| 163 | het/day | 1 |
| 164 | hnep | 1 |
| 165 | home-remedies | 1 |
| 166 | hospitalization/intubation | 1 |
| 167 | hydromorphine | 1 |
| 168 | icidh-2-guidelines | 1 |
| 169 | imiprine | 1 |
| 170 | inoculation-accounted | 1 |
| 171 | iocm-and | 1 |
| 172 | labour.results | 1 |
| 173 | life.reasons | 1 |
| 174 | live-saving | 1 |
| 175 | maciocia | 1 |
| 176 | macrolactins | 1 |
| 177 | mahajanga | 1 |
| 178 | marrakesh | 1 |
| 179 | membranes/preterm | 1 |
| 180 | methane-oxidizers | 1 |
| 181 | mfa/sfa | 1 |
| 182 | mortality.1 | 1 |
| 183 | multiviews | 1 |
| 184 | myostitis | 1 |
| 185 | necrectomy | 1 |
| 186 | nocturia/night | 1 |
| 187 | nonaddressed | 1 |
| 188 | oxytoxinergometrine | 1 |
| 189 | parvalbumins | 1 |
| 190 | patients=86 | 1 |
| 191 | pcps/mofs | 1 |
| 192 | pet-ct-scan | 1 |
| 193 | pet-tracer | 1 |
| 194 | pinpiles | 1 |
| 195 | placebo/day | 1 |
| 196 | pmgenie-3 | 1 |
| 197 | pocd/-pocd | 1 |
| 198 | points-to-consider | 1 |
| 199 | preload-adjustment | 1 |
| 200 | proton-donors/acceptors | 1 |
| 201 | recensoring | 1 |
| 202 | rresults | 1 |
| 203 | rt/ct/ht | 1 |
| 204 | scl-8 | 1 |
| 205 | screening-tools | 1 |
| 206 | sero-surveillance | 1 |
| 207 | smbe | 1 |
| 208 | solocourovac | 1 |
| 209 | soy/wk | 1 |
| 210 | spirinolactone | 1 |
| 211 | sports/sports | 1 |
| 212 | ssi.. | 1 |
| 213 | statins-use | 1 |
| 214 | telehematology | 1 |
| 215 | tgf-β1+tram-34 | 1 |
| 216 | them-especially | 1 |
| 217 | ti-40nb | 1 |
| 218 | time-applicants | 1 |
| 219 | treatment/remission | 1 |
| 220 | tsc-ptc/c60nps | 1 |
| 221 | uretherorrenoscope | 1 |
| 222 | uricosurics | 1 |
| 223 | veers | 1 |
| 224 | ~0.70 | 1 |
| 225 | £13.34 | 1 |
| 226 | £168.97 | 1 |
| 227 | £23.87 | 1 |
| 228 | £4,800 | 1 |
| 229 | £431 | 1 |
| 230 | £578 | 1 |
| 231 | £9114 | 1 |
| 232 | £9294 | 1 |
| 233 | β-hmx | 1 |
| 234 | δe=7.98 | 1 |
| 235 | €1021/person | 1 |
| 236 | €11,822/qaly | 1 |
| 237 | €20.000 | 1 |
| 238 | €5000 | 1 |
| 239 | ∼0.25 | 1 |
| 240 | ≥0.99 | 1 |
| 1 | 'antibacterials | 1 |
| 2 | 'assessments | 1 |
| 3 | 'preparation | 1 |
| 4 | 'value | 5 |
| 5 | 0.005-5μg/ml | 1 |
| 6 | 0.01-10ng/ml | 1 |
| 7 | 0.026-0.341 | 1 |
| 8 | 0.030±0.004μg/kg/min | 1 |
| 9 | 0.06-1.6μg/ml | 1 |
| 10 | 0.070±0.017μg/kg/min | 1 |
| 11 | 0.1-10μg/ml | 1 |
| 12 | 0.20-401.12μg/ml | 1 |
| 13 | 0.5-200ng/ml | 1 |
| 14 | 0.66±0.47mm | 1 |
| 15 | 0.805-0.907 | 1 |
| 16 | 0.82-6.0 | 2 |
| 17 | 0.84∼0.93 | 1 |
| 18 | 0.9869 | 1 |
| 19 | 1.57-1.62 | 1 |
| 20 | 1.59kwh/kgcu | 1 |
| 21 | 1.73-2.77 | 1 |
| 22 | 1/2/3/4/37/20/4/3 | 1 |
| 23 | 100g/d | 1 |
| 24 | 100µg/day | 1 |
| 25 | 13.6-14.1μm | 1 |
| 26 | 130,013 | 1 |
| 27 | 1350-1400°c | 1 |
| 28 | 137-138°c | 1 |
| 29 | 15-18°c | 1 |
| 30 | 177°c | 1 |
| 31 | 180,000°c/min | 1 |
| 32 | 1:5463 | 1 |
| 33 | 1hz-rtms | 1 |
| 34 | 1hz/20hz | 1 |
| 35 | 2-4msv | 1 |
| 36 | 2-furoyl-ligrlo-amide | 1 |
| 37 | 2.1g | 1 |
| 38 | 2.5bar | 1 |
| 39 | 2.9w/kg | 1 |
| 40 | 20μg/ml | 2 |
| 41 | 23.64-1182ng/ml | 1 |
| 42 | 27.0mpa | 1 |
| 43 | 28*/28* | 1 |
| 44 | 28.1°c | 1 |
| 45 | 3.3-8.9 | 1 |
| 46 | 3.6±1.9μg/kg/min | 1 |
| 47 | 4-20°c | 1 |
| 48 | 4.1/patient-year | 1 |
| 49 | 4.4°c | 2 |
| 50 | 45ºc | 2 |
| 51 | 4u/kg | 1 |
| 52 | 5-3000ng/ml | 1 |
| 53 | 5.00-400ng/ml | 1 |
| 54 | 500ms | 4 |
| 55 | 500w | 1 |
| 56 | 57,500 | 1 |
| 57 | 6.4-247.5 | 1 |
| 58 | 708.3 | 1 |
| 59 | 771.8 | 1 |
| 60 | 9.880 | 1 |
| 61 | a-pcs | 1 |
| 62 | accuracy/latency | 1 |
| 63 | aem-70 | 2 |
| 64 | amniofusion | 1 |
| 65 | anthracycline-therapy | 1 |
| 66 | antipsychotic-augmentation | 1 |
| 67 | at/aml | 1 |
| 68 | atomoxetine/placebo | 1 |
| 69 | beta-sympatomimetics | 1 |
| 70 | biofunctionality | 3 |
| 71 | biometabolites | 1 |
| 72 | biovolumes | 1 |
| 73 | c50sevo | 1 |
| 74 | ceftriaxone+vancomycin | 1 |
| 75 | cephapirin/ml | 1 |
| 76 | cetuximab+chemoradiation | 1 |
| 77 | chaihu-shaoyao | 2 |
| 78 | choice | 8,936 |
| 79 | citalopran | 1 |
| 80 | co-acupressure | 1 |
| 81 | co-consumption | 9 |
| 82 | codependency | 13 |
| 83 | coffee/day | 3 |
| 84 | collimomycins | 1 |
| 85 | conscience | 10 |
| 86 | cross-immunity | 3 |
| 87 | ct-ridc | 1 |
| 88 | cyclopheron | 1 |
| 89 | d=1.203 | 1 |
| 90 | domicile | 6 |
| 91 | double-slit | 1 |
| 92 | drinking-with-partner | 1 |
| 93 | druglikeness | 4 |
| 94 | dysautonomias | 3 |
| 95 | education/preparation | 1 |
| 96 | efficacy/evidence | 1 |
| 97 | endosheaths | 1 |
| 98 | ethnopharmacovigilance | 1 |
| 99 | euro315 | 1 |
| 100 | euro99 | 1 |
| 101 | fallibility | 8 |
| 102 | family-screening | 1 |
| 103 | fancy | 7 |
| 104 | femn4ox/mcm-41 | 1 |
| 105 | feneticillin | 1 |
| 106 | flow-sorting | 1 |
| 107 | force-displacement | 8 |
| 108 | freshness-indices | 1 |
| 109 | g=3 | 1 |
| 110 | gaba-agonism | 1 |
| 111 | gabapentin-pregabalin | 1 |
| 112 | galactolipid/day | 1 |
| 113 | galloylation | 2 |
| 114 | gonopod | 4 |
| 115 | gum/day | 1 |
| 116 | het/day | 1 |
| 117 | hnep | 1 |
| 118 | home-remedies | 1 |
| 119 | hospitalization/intubation | 1 |
| 120 | humanization | 4 |
| 121 | hydromorphine | 1 |
| 122 | icidh-2-guidelines | 1 |
| 123 | imiprine | 1 |
| 124 | indianization | 2 |
| 125 | inoculation-accounted | 1 |
| 126 | iocm-and | 1 |
| 127 | keflex | 2 |
| 128 | labour.results | 1 |
| 129 | legitimisation | 4 |
| 130 | lepchas | 3 |
| 131 | life.reasons | 1 |
| 132 | live-saving | 1 |
| 133 | lynchpin | 3 |
| 134 | maciocia | 1 |
| 135 | macrolactins | 1 |
| 136 | mahajanga | 1 |
| 137 | marrakesh | 1 |
| 138 | mega-doses | 3 |
| 139 | membranes/preterm | 1 |
| 140 | methane-oxidizers | 1 |
| 141 | mfa/sfa | 1 |
| 142 | milk/kg | 4 |
| 143 | mortality.1 | 1 |
| 144 | multiviews | 1 |
| 145 | myostitis | 1 |
| 146 | mystique | 3 |
| 147 | nac-cc | 2 |
| 148 | necrectomy | 1 |
| 149 | nits | 2 |
| 150 | nocturia/night | 1 |
| 151 | non-inferioritylequivalence | 2 |
| 152 | nonaddressed | 1 |
| 153 | oil/day/person | 2 |
| 154 | ovacheck | 2 |
| 155 | overseers | 3 |
| 156 | oxytoxinergometrine | 1 |
| 157 | parvalbumins | 1 |
| 158 | patients=86 | 1 |
| 159 | pcps/mofs | 1 |
| 160 | pet-ct-scan | 1 |
| 161 | pet-tracer | 1 |
| 162 | photomicrography | 2 |
| 163 | pinpiles | 1 |
| 164 | placebo/day | 1 |
| 165 | pmgenie-3 | 1 |
| 166 | pocd/-pocd | 1 |
| 167 | pocts | 7 |
| 168 | points-to-consider | 1 |
| 169 | positivization | 2 |
| 170 | postcrania | 2 |
| 171 | preload-adjustment | 1 |
| 172 | professorship | 3 |
| 173 | proton-donors/acceptors | 1 |
| 174 | protonation/deprotonation | 3 |
| 175 | pseudo-foveas | 5 |
| 176 | radiofluorination | 2 |
| 177 | radioopacity | 2 |
| 178 | re-screening | 3 |
| 179 | reachability | 2 |
| 180 | recensoring | 1 |
| 181 | resistome | 2 |
| 182 | ring-closure | 3 |
| 183 | rresults | 1 |
| 184 | rt/ct/ht | 1 |
| 185 | scientology | 2 |
| 186 | scl-8 | 1 |
| 187 | sclerotization | 4 |
| 188 | screening-tools | 1 |
| 189 | secnidazol | 3 |
| 190 | self-pyrolysis | 2 |
| 191 | sero-efficacy | 2 |
| 192 | sero-surveillance | 1 |
| 193 | set-shift | 3 |
| 194 | sight | 104 |
| 195 | single-doses | 3 |
| 196 | smbe | 1 |
| 197 | solocourovac | 1 |
| 198 | somato-types | 2 |
| 199 | sorafenib+nutlin-3 | 3 |
| 200 | soy/wk | 1 |
| 201 | spirinolactone | 1 |
| 202 | sports/sports | 1 |
| 203 | ssi.. | 1 |
| 204 | statins-use | 1 |
| 205 | stereoinduction | 2 |
| 206 | storvas | 2 |
| 207 | surname | 3 |
| 208 | swahili | 6 |
| 209 | tale | 15 |
| 210 | telehematology | 1 |
| 211 | tgf-β1+tram-34 | 1 |
| 212 | them-especially | 1 |
| 213 | ti-40nb | 1 |
| 214 | time-applicants | 1 |
| 215 | trans-isomers | 3 |
| 216 | treatment/remission | 1 |
| 217 | tsc-ptc/c60nps | 1 |
| 218 | uretherorrenoscope | 1 |
| 219 | uricosurics | 1 |
| 220 | veers | 1 |
| 221 | xxmd | 5 |
| 222 | yews | 7 |
| 223 | ~0.70 | 1 |
| 224 | £13.34 | 1 |
| 225 | £168.97 | 1 |
| 226 | £23.87 | 1 |
| 227 | £4,800 | 1 |
| 228 | £431 | 1 |
| 229 | £45 | 2 |
| 230 | £578 | 1 |
| 231 | £9114 | 1 |
| 232 | £9294 | 1 |
| 233 | β-hmx | 1 |
| 234 | δe=7.98 | 1 |
| 235 | €1021/person | 1 |
| 236 | €11,822/qaly | 1 |
| 237 | €20.000 | 1 |
| 238 | €5000 | 1 |
| 239 | ∼0.25 | 1 |
| 240 | ≥0.99 | 1 |
| 1 | 28*/28* | 1 |
| 2 | ssi.. | 1 |
| 3 | 0.82-6.0 | 2 |
| 4 | €20.000 | 1 |
| 5 | €5000 | 1 |
| 6 | 57,500 | 1 |
| 7 | £4,800 | 1 |
| 8 | aem-70 | 2 |
| 9 | ~0.70 | 1 |
| 10 | 9.880 | 1 |
| 11 | mortality.1 | 1 |
| 12 | £431 | 1 |
| 13 | femn4ox/mcm-41 | 1 |
| 14 | 0.026-0.341 | 1 |
| 15 | 1.57-1.62 | 1 |
| 16 | pmgenie-3 | 1 |
| 17 | sorafenib+nutlin-3 | 3 |
| 18 | 708.3 | 1 |
| 19 | 1/2/3/4/37/20/4/3 | 1 |
| 20 | d=1.203 | 1 |
| 21 | 130,013 | 1 |
| 22 | 1:5463 | 1 |
| 23 | 0.84∼0.93 | 1 |
| 24 | g=3 | 1 |
| 25 | £9114 | 1 |
| 26 | tgf-β1+tram-34 | 1 |
| 27 | £13.34 | 1 |
| 28 | £9294 | 1 |
| 29 | 6.4-247.5 | 1 |
| 30 | euro315 | 1 |
| 31 | ∼0.25 | 1 |
| 32 | £45 | 2 |
| 33 | patients=86 | 1 |
| 34 | 0.805-0.907 | 1 |
| 35 | 1.73-2.77 | 1 |
| 36 | £23.87 | 1 |
| 37 | £168.97 | 1 |
| 38 | scl-8 | 1 |
| 39 | 771.8 | 1 |
| 40 | £578 | 1 |
| 41 | δe=7.98 | 1 |
| 42 | 3.3-8.9 | 1 |
| 43 | 0.9869 | 1 |
| 44 | ≥0.99 | 1 |
| 45 | euro99 | 1 |
| 46 | mfa/sfa | 1 |
| 47 | mahajanga | 1 |
| 48 | maciocia | 1 |
| 49 | postcrania | 2 |
| 50 | 27.0mpa | 1 |
| 51 | ti-40nb | 1 |
| 52 | solocourovac | 1 |
| 53 | nac-cc | 2 |
| 54 | ct-ridc | 1 |
| 55 | 1350-1400°c | 1 |
| 56 | 4-20°c | 1 |
| 57 | 28.1°c | 1 |
| 58 | 4.4°c | 2 |
| 59 | 177°c | 1 |
| 60 | 15-18°c | 1 |
| 61 | 137-138°c | 1 |
| 62 | 45ºc | 2 |
| 63 | 100g/d | 1 |
| 64 | pocd/-pocd | 1 |
| 65 | nonaddressed | 1 |
| 66 | inoculation-accounted | 1 |
| 67 | xxmd | 5 |
| 68 | iocm-and | 1 |
| 69 | gonopod | 4 |
| 70 | smbe | 1 |
| 71 | choice | 8,936 |
| 72 | ethnopharmacovigilance | 1 |
| 73 | sero-surveillance | 1 |
| 74 | efficacy/evidence | 1 |
| 75 | conscience | 10 |
| 76 | non-inferioritylequivalence | 2 |
| 77 | 2-furoyl-ligrlo-amide | 1 |
| 78 | tale | 15 |
| 79 | domicile | 6 |
| 80 | surname | 3 |
| 81 | resistome | 2 |
| 82 | hydromorphine | 1 |
| 83 | imiprine | 1 |
| 84 | oxytoxinergometrine | 1 |
| 85 | spirinolactone | 1 |
| 86 | uretherorrenoscope | 1 |
| 87 | ring-closure | 3 |
| 88 | co-acupressure | 1 |
| 89 | statins-use | 1 |
| 90 | 'value | 5 |
| 91 | mystique | 3 |
| 92 | 2.1g | 1 |
| 93 | milk/kg | 4 |
| 94 | 4u/kg | 1 |
| 95 | 2.9w/kg | 1 |
| 96 | re-screening | 3 |
| 97 | family-screening | 1 |
| 98 | recensoring | 1 |
| 99 | flow-sorting | 1 |
| 100 | live-saving | 1 |
| 101 | marrakesh | 1 |
| 102 | swahili | 6 |
| 103 | ovacheck | 2 |
| 104 | soy/wk | 1 |
| 105 | 5-3000ng/ml | 1 |
| 106 | 0.5-200ng/ml | 1 |
| 107 | 5.00-400ng/ml | 1 |
| 108 | 0.01-10ng/ml | 1 |
| 109 | 23.64-1182ng/ml | 1 |
| 110 | 0.1-10μg/ml | 1 |
| 111 | 20μg/ml | 2 |
| 112 | 0.20-401.12μg/ml | 1 |
| 113 | 0.005-5μg/ml | 1 |
| 114 | 0.06-1.6μg/ml | 1 |
| 115 | cephapirin/ml | 1 |
| 116 | at/aml | 1 |
| 117 | secnidazol | 3 |
| 118 | 0.66±0.47mm | 1 |
| 119 | membranes/preterm | 1 |
| 120 | gaba-agonism | 1 |
| 121 | 13.6-14.1μm | 1 |
| 122 | pet-ct-scan | 1 |
| 123 | citalopran | 1 |
| 124 | ceftriaxone+vancomycin | 1 |
| 125 | gabapentin-pregabalin | 1 |
| 126 | feneticillin | 1 |
| 127 | 180,000°c/min | 1 |
| 128 | 0.030±0.004μg/kg/min | 1 |
| 129 | 0.070±0.017μg/kg/min | 1 |
| 130 | 3.6±1.9μg/kg/min | 1 |
| 131 | lynchpin | 3 |
| 132 | treatment/remission | 1 |
| 133 | amniofusion | 1 |
| 134 | hospitalization/intubation | 1 |
| 135 | cetuximab+chemoradiation | 1 |
| 136 | galloylation | 2 |
| 137 | radiofluorination | 2 |
| 138 | protonation/deprotonation | 3 |
| 139 | 'preparation | 1 |
| 140 | education/preparation | 1 |
| 141 | legitimisation | 4 |
| 142 | antipsychotic-augmentation | 1 |
| 143 | indianization | 2 |
| 144 | humanization | 4 |
| 145 | sclerotization | 4 |
| 146 | positivization | 2 |
| 147 | stereoinduction | 2 |
| 148 | co-consumption | 9 |
| 149 | cyclopheron | 1 |
| 150 | €1021/person | 1 |
| 151 | oil/day/person | 2 |
| 152 | chaihu-shaoyao | 2 |
| 153 | atomoxetine/placebo | 1 |
| 154 | c50sevo | 1 |
| 155 | hnep | 1 |
| 156 | professorship | 3 |
| 157 | 2.5bar | 1 |
| 158 | 4.1/patient-year | 1 |
| 159 | pet-tracer | 1 |
| 160 | points-to-consider | 1 |
| 161 | drinking-with-partner | 1 |
| 162 | pseudo-foveas | 5 |
| 163 | lepchas | 3 |
| 164 | dysautonomias | 3 |
| 165 | storvas | 2 |
| 166 | uricosurics | 1 |
| 167 | beta-sympatomimetics | 1 |
| 168 | a-pcs | 1 |
| 169 | freshness-indices | 1 |
| 170 | home-remedies | 1 |
| 171 | pinpiles | 1 |
| 172 | biovolumes | 1 |
| 173 | icidh-2-guidelines | 1 |
| 174 | somato-types | 2 |
| 175 | mega-doses | 3 |
| 176 | single-doses | 3 |
| 177 | biometabolites | 1 |
| 178 | pcps/mofs | 1 |
| 179 | endosheaths | 1 |
| 180 | self-pyrolysis | 2 |
| 181 | myostitis | 1 |
| 182 | 'antibacterials | 1 |
| 183 | screening-tools | 1 |
| 184 | 500ms | 4 |
| 185 | 1hz-rtms | 1 |
| 186 | collimomycins | 1 |
| 187 | parvalbumins | 1 |
| 188 | macrolactins | 1 |
| 189 | life.reasons | 1 |
| 190 | tsc-ptc/c60nps | 1 |
| 191 | overseers | 3 |
| 192 | veers | 1 |
| 193 | trans-isomers | 3 |
| 194 | methane-oxidizers | 1 |
| 195 | proton-donors/acceptors | 1 |
| 196 | druglikeness | 4 |
| 197 | pocts | 7 |
| 198 | nits | 2 |
| 199 | labour.results | 1 |
| 200 | rresults | 1 |
| 201 | time-applicants | 1 |
| 202 | 'assessments | 1 |
| 203 | sports/sports | 1 |
| 204 | multiviews | 1 |
| 205 | yews | 7 |
| 206 | set-shift | 3 |
| 207 | rt/ct/ht | 1 |
| 208 | nocturia/night | 1 |
| 209 | sight | 104 |
| 210 | double-slit | 1 |
| 211 | force-displacement | 8 |
| 212 | preload-adjustment | 1 |
| 213 | 1.59kwh/kgcu | 1 |
| 214 | 2-4msv | 1 |
| 215 | 500w | 1 |
| 216 | keflex | 2 |
| 217 | β-hmx | 1 |
| 218 | galactolipid/day | 1 |
| 219 | coffee/day | 3 |
| 220 | 100µg/day | 1 |
| 221 | gum/day | 1 |
| 222 | placebo/day | 1 |
| 223 | het/day | 1 |
| 224 | sero-efficacy | 2 |
| 225 | fancy | 7 |
| 226 | codependency | 13 |
| 227 | accuracy/latency | 1 |
| 228 | telehematology | 1 |
| 229 | scientology | 2 |
| 230 | photomicrography | 2 |
| 231 | €11,822/qaly | 1 |
| 232 | them-especially | 1 |
| 233 | necrectomy | 1 |
| 234 | anthracycline-therapy | 1 |
| 235 | radioopacity | 2 |
| 236 | biofunctionality | 3 |
| 237 | reachability | 2 |
| 238 | fallibility | 8 |
| 239 | cross-immunity | 3 |
| 240 | 1hz/20hz | 1 |